CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 209 enrolled
Drug / intervention
OPC-12759 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01660256
NCT01660256Phase 3Completed

Confirmatory Study of OPC-12759 Ophthalmic Solution in Patients With Dry Eye

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Aug 8, 2012·Updated May 5, 2021

In Brief

A Phase 3 clinical trial evaluating OPC-12759 and Placebo for Dry Eye. Completed, enrolled 209 participants across 4 sites.

Detailed Summary

The purpose of this study is to verify whether OPC-12759 ophthalmic solution is effective compared with placebo in dry eye patients. OPC-12759 ophthalmic suspension will be used as a reference drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2012
Enrollment StartAug 1, 2012
Primary CompletionMar 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.9 years ago

Interventions

OPC-12759drug

Instillation, 4 times/day for 4 weeks

Placebodrug